- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT01109186
Anti-BK Virus Immune Response and Kidney Transplantation (BKv)
Role of Specific Immune Cellular Response in the Control of BK Virus Infection: Prospective Study, Monocentric and Longitudinal During the First Nine Months After a Kidney Transplantation
BK virus infections are very frequent during months following a kidney transplantation: a viral reactivation is observed for almost 50% of patients during first year. This reactivation leads to a viremia for 10 to 15% of patient during this same period. The most frequent complication is interstitial nephritis for 2 to 8% of patients (27 patients representing 2.7% during 6 years in Nantes).
An intensive et persisting viral replication, assessed by detection of high blood viral load, could evolved to a viral nephropathy which lead to a very pejorative functional issue for the graft.
Biological follow-up of these infections lay on the measures of viral load. Their positivity must alert the physician and lead him to modulate immunosuppressive treatment.
Actually, there is no real consensus about the modalities of pharmacological immunosuppression decrease (decrease dose or change of molecule).
Specific lymphocytic anti-BKv evaluated on several cohorts of patients permit to prove:
- weakness of immune cellular response for patient with high viremia
- increase of this response when viral load decrease These studies laid on detection of INFg synthesis by Elispot after stimulation with viral antigens and in vitro cellular expansion.
New prospective and longitudinal data comparing the immune cellular response (systematic and early) after graft between patients controlling or not BKv infection are necessary to improve the comprehension of illness natural history.
The investigators propose to enlarge the investigation of anti-BKv immune cellular response to other functions than IFNg synthesis in the aim of detecting the eventual role of polyfunctional lymphocytes for infection control. Furthermore, the investigators propose to identify better diagnostic and prognostic makers.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Tipo de estudio
Inscripción (Actual)
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
-
Nantes, Francia, 44000
- Nantes' Univeristy hospital
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Método de muestreo
Población de estudio
Descripción
Inclusion Criteria:
- Kidney-transplanted patient, since less than 30 days
- Older than 18 years old
- Treatment with tacrolimus and mycophénolate mofetil
Exclusion Criteria:
- No informed consent
- Pregnant women
- Patient under legal guardianship
- Treated by ciclosporin or mTOR-inhibitor
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
Cohortes e Intervenciones
Grupo / Cohorte |
Intervención / Tratamiento |
---|---|
kidney-transplanted patients
|
blood sample at M1, M2, M3; M4; M5, M6, M7, M8 and M9 after kidney transplantation
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Comparison of the level of response between patient with a "non-controlled infection" and patients for who the blood viral load is under 103 copBKv/ml.
Periodo de tiempo: at 1month, 2months, 3months, 4, 5, 6, 7, 8 and 9 months after kidney transplantation
|
Analyse the role of T-lymphocytes response in the control of BKv infection
|
at 1month, 2months, 3months, 4, 5, 6, 7, 8 and 9 months after kidney transplantation
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Analyse of the other causes that could influence the occurence of a viremia higher than 103 copBKv/ml
Periodo de tiempo: at 1month, 2months, 3months, 4, 5, 6, 7, 8 and 9 months after kidney transplantation
|
Other causes for abnormal viremia
|
at 1month, 2months, 3months, 4, 5, 6, 7, 8 and 9 months after kidney transplantation
|
Measurement of histological consequences of a BKv non-controlled infection during the first year post-graft
Periodo de tiempo: at 12 months after kidney transplantation
|
Determine the frequence of occurence of nephropathy due to BKv for the population with a non-controlled infection
|
at 12 months after kidney transplantation
|
Measurement of increase of immune response due to modifications of immunosuppressive treatment for patient with a non-controlled infection
Periodo de tiempo: at 1, 3 et 6 months after modification of immunosuppressive treatment
|
Comparision between the level of immune response and the time when the first viremia is higher than 103 copBKv/ml and 1, 3 et 6 months after modification of immunosuppressive treatment.
|
at 1, 3 et 6 months after modification of immunosuppressive treatment
|
Colaboradores e Investigadores
Patrocinador
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Estimar)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Otros números de identificación del estudio
- BRD/10/03-ZF
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .
Ensayos clínicos sobre biological parameters
-
GlaxoSmithKlineTerminadoInfecciones, PapilomavirusTaiwán, Tailandia, Brasil
-
GlaxoSmithKlineTerminadoInfecciones, PapilomavirusEstados Unidos, Canadá
-
GlaxoSmithKlineTerminadoSarampión | Rubéola | Paperas | VaricelaIndia
-
GlaxoSmithKlineTerminadoHepatitis B | Tétanos | Difteria | Tos ferina acelular | Poliomielitis | Haemophilus influenzae tipo bFinlandia
-
GlaxoSmithKlineTerminadoSarampión | Rubéola | Paperas | Vacuna contra sarampión, paperas y rubéolaEstados Unidos, Puerto Rico
-
Shanghai Institute Of Biological ProductsTerminado
-
Jiangsu Province Centers for Disease Control and...TerminadoEfecto adverso e inmunogenicidad de la vacunaPorcelana
-
GlaxoSmithKlineThe PATH Malaria Vaccine Initiative (MVI)Terminado
-
GlaxoSmithKlineTerminado